African Swine Fever

NEW YORK, April 14, 2024 /PRNewswire/ -- The veterinary artificial insemination (AI) Market is estimated for remarkable growth, with experts predicting a staggering increase of USD 1.03 billion by 2027. This surge, driven by factors like enhanced livestock multiplication and disease control measures, promises a transformative impact on global agriculture. Download a Sample Report! Continue Reading Technavio has announced its latest market research report titled Global Veterinary Artificial Insemination Market 2023-2027 Market Dynamics: Livestock multiplication emerges as a pivotal driver, empowering farmers to amplify yields while mitigating disease risks through AI techniques. The adoption of AI facilitates safer reproduction processes, extending livestock lifespans and curbing investment in disease management. Moreover, by harnessing advanced genetics and efficient crossbreeding, AI ensures superior livestock quality and increased productivity, addressing the mounting demand for animal proteins worldwide. Trending Initiatives: Government initiatives worldwide are fueling market growth, aiming to fortify animal protein supply chains, enhance livestock genetics, and combat disease transmission risks. These strategic interventions underscore a global commitment to sustainable agriculture and food security. Innovative Advancements: Advances in bovine genetics spearhead market expansion, leveraging genomic selection to optimize livestock productivity and quality. By identifying desirable traits through DNA analysis, farmers can enhance herd genetics, fostering a new era of agricultural efficiency. For more insights on the market - Download a Sample Report! Challenges: Despite its potential, the market grapples with challenges such as the hefty investment required for AI processes and equipment. Additionally, the scarcity of skilled veterinary professionals poses a significant hurdle. Moreover, infectious diseases remain a concern, underscoring the importance of rigorous screening and preventive measures. Key Players: Leading companies like Agtech, Bovine Elite LLC, and Zoetis are driving innovation through strategic alliances and product launches, consolidating their market presence. These players epitomize the industry's dynamism, continually pushing the boundaries of AI technology. Segment Analysis: The animal husbandry segment emerges as a frontrunner, witnessing exponential growth fueled by meticulous disease control and reproduction management practices. This segment's sustained expansion underscores its pivotal role in meeting rising livestock demands. To learn more about this report- Download a Sample Report! Regional Insights: North America emerges as a key contributor, with the US spearheading market growth. Sustainable livestock management practices in the region fuel demand for AI solutions, signaling a paradigm shift in agricultural practices. Conclusion: The veterinary AI market stands at the cusp of a transformative journey, poised to revolutionize livestock reproduction and elevate global agricultural standards. With innovation driving progress and strategic initiatives shaping the landscape, the stage is set for unprecedented growth and development in the coming years. Analyst Review The Veterinary Artificial Insemination (AI) Market is a critical segment within the broader livestock and poultry value chains, catering to the reproductive needs of various animal species. With a global focus on sustainable food production and animal well-being, the demand for advanced reproductive technologies like AI has surged in recent years. Telephonic assistance, offered by expert veterinarians, supports farmers and livestock owners in navigating the complexities of AI procedures and ensuring optimal breeding outcomes. In the realm of AI, employees of veterinary hospitals and specialized AI service providers play pivotal roles. They are proficient in employing superior breeding techniques, genetic selection, and artificial insemination procedures to enhance the genetic base of animal populations. However, challenges persist, including the prevalence of transmitted diseases such as vibriosis, bovine trichomoniasis, and African swine fever, particularly in regions like the Asia-Pacific. To mitigate disease risks and improve reproductive efficiency, stringent hygiene protocols are employed, especially in veterinary hospitals like ABC Veterinary Hospital. Veterinarians conduct thorough reproductive health assessments, fertility testing, and ultrasound examinations to gauge animals' suitability for AI procedures. Estrus synchronization and ovarian stimulation protocols further optimize insemination timing and frequency. Market participants in the veterinary AI sector encompass a diverse range of entities, including public sector organizations, private companies like Cogent and AB Europe, academic institutions, and international organizations like the Food and Agriculture Organization of the United Nations. They offer a spectrum of services, from distributing AI equipment and consumables to providing AI products and genetic testing services. Key considerations in the AI market revolve around genetic enhancements, resistance to illness, and breeding outcomes tailored to consumer preferences. Genetic data, including Predicted Transmitting Abilities (PTAs), facilitates informed breeding decisions aimed at improving meat quality, milk yield, and temperament of animals. However, challenges such as semen shortages and travel restrictions have prompted innovative solutions like sexed sperm technology and the adoption of e-commerce platforms for AI services. Moreover, advancements in cryopreservation techniques ensure the long-term viability of genetic material, enabling the global exchange of superior genetic traits. Overall, the Veterinary Artificial Insemination Market continues to evolve, driven by the quest for sustainable food production and the optimization of animal efficiency. Through collaborative efforts among market participants and supportive initiatives, the industry endeavors to address emerging challenges while fulfilling the growing demand for animal-sourced food products. To learn more about this report- Download a Sample Report! Market Overview The Veterinary Artificial Insemination (AI) Market plays a pivotal role in enhancing livestock and poultry value chains by offering telephonic assistance to employees engaged in animal husbandry. Employing superior breeds of animals through genetic selection ensures quality offspring, while AI procedures further amplify breeding efficacy. Employing advanced techniques, such as artificial insemination, mitigates transmitted diseases like vibriosis and bovine trichomoniasis, safeguarding animal health. Crossbreeding strategies are optimized through AI, fostering the development of robust genetic pools. The market's growth is propelled by the demand for enhanced breeding techniques and the assurance of healthy animal-sourced food. With continual advancements in AI technology, the veterinary sector anticipates significant expansion, catering to the evolving needs of livestock management worldwide. To learn more about this report- Download a Sample Report! Related Reports The pain management devices market size is estimated to grow at a CAGR of 8.92% between 2022 and 2027. The market size is forecast to increase by USD 2,705.68 million. Furthermore, this report extensively covers market segmentation by application (neuropathic pain, musculoskeletal disorder, cancer, facial and migraine, and others), product (neurostimulation devices, infusion pumps, and ablation devices), and geography (North America, Asia, Europe, and Rest of World (ROW)). The growing demand for drug-free therapy is a key factor driving the market growth during the forecast period. The artificial bone market size is estimated to grow by USD 170.77 million at a CAGR of 8.5% between 2022 and 2027. Furthermore, this report extensively covers market segmentation by material segment (ceramics, hydroxyapatite, composite, polymer, and others), end-user (hospitals, specialty clinics, and research organizations), and geography (North America, Europe, Asia, and Rest of World (ROW)). The increasing awareness and accessibility to advanced medical treatments are key factors driving the market growth during the forecast period. About US Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

Alpha Sophia is set to make waves at the LSI USA 2024 Emerging MedTech Summit in Dana Point, California, from March 18-22. Led by CEO Paul-Lukas Hoffschmidt, Alpha Sophia will unveil a major product update during the event, promising significant enhancements to its platform and model. Hoffschmidt will spearhead a thought leadership session on March 21 alongside industry experts Brad Patt (Tetrous), Robert Hamilton (Neurasignal), and James Peacock (Nocira). This session will mark the formal announcement of game-changing improvements to the Alpha Sophia platform, tailored to meet the needs of medtech sales leaders. The updates showcased at the LSI summit are poised to redefine the landscape of go-to-market tactics for the Medtech industry, offering innovative solutions that address the dynamic challenges faced by professionals in this field. Alpha Sophia remains committed to driving meaningful change and empowering sales professionals with cutting-edge tools and strategies. Baseimmune, a biotech company that uses proprietary, deep learning AI to predict future pathogen mutations to generate novel vaccines, has raised $11.3 million in a Series A funding round led by new investors MSD Global Health Innovation Fund and IQ Capital. Existing investors also too part in the round, including Hoxton Ventures, Creator Fund, Beast Ventures and Maki.vc. The funding will be used to accelerate development of Baseimmune’s three vaccine candidates currently in preclinical development for African swine fever, coronavirus, and malaria. The funding will also be used to advance its technology, add staff, increase the number of programs in development and accelerate new vaccine programs. To read more, click here. Abridge, which focuses on generative AI for clinical documentation, has raised $150 million in a Series C funding round. Abridge has also embarked on a new enterprise agreement with the Yale New Haven Health System, according to a press release. Lightspeed Venture Partners led the round and will also join the board. Other new and existing investors include co-lead Redpoint Ventures, with support from IVP, Spark Capital, Union Square Ventures, Bessemer Venture Partners, Wittington Ventures, Mass General Brigham Artificial Intelligence and Digital Innovation Fund (AIDIF), Kaiser Permanente Ventures, and CVS Health Ventures. To read more, click here. Carewell, an online retailer focused serving family caregivers with tools and resources to care for their loved ones, has raised a $24.7 million Series B round. The goal is to further accelerate streamlining access to home health products, according to a press release. The principals of MBF Healthcare led the round, with participation from existing investors Sageview Capital and Headline among others. Additionally, the company has made several senior level hires amidst plans to relocate their headquarters to Miami. Additional investors in this round of funding include Primetime Partners, Nextview, Florida Opportunity Fund, and Anchor. To read more, click here. Redi Health has closed $14 million in a Series B funding round. The funding round was led by Blue Heron Capital. North Coast Ventures and existing investors Refinery Ventures, Mutual Capital Partners, Rev1 Ventures and M25 also took pat in the round. Redi Health combines health management technology to help people manage chronic conditions with digital pharma services. It will use the fresh capital to develop and launch new products, expand its network and accelerate overall growth, according to a press release. To read more, click here.

While the world learned in 2020 the importance of designing effective vaccines quickly, Baseimmune was a year ahead of the curve.  “I love vaccines because they’re the only method to eradicate diseases from the planet,” CEO Joshua Blight told FirstWord. “But we need to be smarter than the pathogen.” He co-founded Baseimmune in 2019 with chief scientific officer Ariane Gomes after the pair met at the University of Oxford’s Jenner Institute, where they envisioned an evolution-informed method of creating vaccines. To put that vision into practice, they recruited the company’s third co-founder and chief technology officer Phillip Kemlo, a software engineer who built the company’s AI-driven vaccine design platform.Now Baseimmune has raised a $11.3 million-series A on the strength of that platform and the three preclinical vaccines it has produced so far, including for coronavirus and malaria.  The company’s hybrid business model allows for internal asset development, with out-licensing the goal after each programme has been de-risked, as well as partnerships for vaccine development. New investors MSD Global Health Innovation Fund and IQ Capital co-led Monday’s round, which saw participation from existing investors including Hoxton Ventures, Creator Fund, Beast Ventures and Maki.vc.Preempting evolutionBaseimmune’s vaccine algorithm designs synthetic antigens that are capable of triggering a wide-ranging immune response against multiple facets of a pathogen, not just a single protein, as is the norm today. Plus, the company’s antigens take into account pathogenic aspects that don’t yet exist in nature – part of its goal to “future proof” vaccines against eventual mutations. “Instead of just chasing the next mutation, the next variant, we’re trying to understand evolution, the evasion of pathogens, and build that into a vaccine,” Gomes told FirstWord. The algorithm analyses genomic, epidemiological, immunological, clinical and evolutionary data to predict how a pathogen might evolve, which informs the design of each synthetic antigen. Baseimmune isn’t just an AI company though, Blight emphasised. “We’re directed by science, but facilitated by technology,” he said. “Everything we’re doing computationally is validated in our lab.”Proving its powerBaseimmune’s first three programmes were chosen to prove several points about the technology: its applicability to any kind of pathogen; its efficacy against relatively unknown targets; and its impact on public health.  That’s why, to showcase how the platform is universal, BaseImmune chose one human pathogen, one veterinary virus, and a parasite to initially develop vaccines against.  Malaria in particular is especially difficult to prevent, which makes it a great proof-of-concept for the algorithm, Blight said. The disease-causing parasite, which is more genetically complex than a typical virus, presents differently at each stage of its life cycle, and relies on mosquitoes to infect humans. “One of the benefits of what our platform can do is that we can target a large number of [malaria] genes in one single antigen,” Blight said. “If you’re able to cover enough of these, then you can have a significant impact in preventing infection.”African swine fever was also chosen because there isn’t a lot of existing experimental data for the virus. That contrasts sharply with vaccine development today, which often draws on a deep body of literature to decide which antigen is most likely to trigger a robust immune response – as was the case with COVID-19 vaccines, which all target the spike protein, thanks to years of research on coronaviruses showing the protein’s necessity to invade host cells. With African swine fever, “we don’t have that world of resources in terms of research,” which may also be lacking for a pathogen that emerges in the future, Gomes said. “Our technology can bridge that knowledge gap by looking for rules that are common to all pathogens, like evolution and evasion.” Finally, all three programmes are intended to address critical public health concerns. That’s why Baseimmune is targeting the entirety of the coronavirus family – like the common cold – with its vaccine, not just COVID-19.